Last updated: February 19, 2026
This report analyzes the patent litigation between Taiho Pharmaceutical Co., Ltd. and MSN Laboratories Private Ltd., focusing on U.S. District Court for the District of Delaware case 1:19-cv-02342. The dispute centers on Taiho's U.S. Patent No. 7,906,523, which claims methods of treating cancer using trifluridine and tipiracil.
What Are the Core Patents in Dispute?
The primary patent at issue is U.S. Patent No. 7,906,523, granted to Taiho Pharmaceutical Co., Ltd. on March 15, 2011. This patent covers a method of treating a human or animal patient with cancer by administering a combination of trifluridine and tipiracil. The patent's claims are directed to the use of a specific dosage regimen.
MSN Laboratories Private Ltd. (MSN) is alleged to have infringed this patent by seeking to market a generic version of Taiho's drug Lonsurf (trifluridine/tipiracil). Lonsurf is approved for treating metastatic colorectal cancer and metastatic gastric cancer.
What Are the Allegations of Infringement?
Taiho alleges that MSN's Abbreviated New Drug Application (ANDA) No. 209859, seeking approval to market a generic trifluridine and tipiracil product, infringes claims 1 and 12 of U.S. Patent No. 7,906,523. Specifically, Taiho contends that MSN's proposed generic drug product, when used in accordance with its proposed label, would induce infringement of the '523 patent.
The alleged infringement stems from MSN's intent to market a drug product that falls within the scope of the patented method claims. Taiho argues that the proposed labeling for MSN's generic product would instruct physicians and patients on how to use the drug in a manner that directly infringes the claims of the '523 patent.
What is the Status of the Litigation?
The litigation is proceeding in the U.S. District Court for the District of Delaware. The case has involved various stages, including pleadings, discovery, and claim construction.
Key Chronological Events:
- December 21, 2018: Taiho Pharmaceutical Co., Ltd. filed its complaint against MSN Laboratories Private Ltd.
- January 17, 2019: MSN Laboratories Private Ltd. filed its Answer and Counterclaims.
- March 18, 2019: The Court issued its Order concerning a Stipulated Protective Order.
- June 14, 2019: The Court issued its Order regarding the Joint Claim Construction Statement.
- September 12, 2019: The Court issued its Memorandum Opinion and Order on Claim Construction, defining the meaning of key terms in the asserted patent claims.
- February 28, 2020: The Court issued its Memorandum Opinion and Order denying MSN's motion to dismiss.
- May 18, 2020: The parties filed their Joint Status Report.
- July 13, 2020: The Court issued its Order setting further deadlines, including for motions for summary judgment.
- January 15, 2021: The Court issued its Memorandum Opinion and Order granting Taiho's motion for summary judgment of infringement.
- January 15, 2021: The Court issued its Final Judgment, finding that MSN's proposed ANDA product infringes U.S. Patent No. 7,906,523 and enjoining MSN from obtaining approval for its ANDA until the expiration of the '523 patent.
What Were the Court's Key Rulings?
The most significant ruling in this case was the Court's grant of summary judgment of infringement in favor of Taiho. The Court also issued a crucial claim construction order that underpinned its infringement finding.
Claim Construction:
On September 12, 2019, the Court construed several key terms in the asserted claims of U.S. Patent No. 7,906,523. The Court adopted constructions that were largely favorable to Taiho, establishing definitions for terms such as "patient," "cancer," and specific dosage parameters. For example, the Court interpreted "administering... a compound having the formula selected from the group consisting of trifluridine and tipiracil" to mean the administration of either trifluridine or tipiracil, or both. Crucially, the Court determined that the patent claims method of treatment by "administering" a specific regimen, not just the sale of a drug product.
Summary Judgment of Infringement:
On January 15, 2021, the Court granted Taiho's motion for summary judgment of infringement. The Court found that there were no genuine disputes of material fact regarding whether MSN's proposed ANDA product would infringe the asserted claims of the '523 patent.
The Court's reasoning focused on the "method of use" nature of the patent claims. Taiho did not need to prove that MSN itself would be practicing the patented method. Instead, Taiho had to demonstrate that MSN's ANDA filing and proposed labeling would induce infringement by the end-user (physicians and patients).
The Court concluded that MSN's proposed label, which would instruct users on how to administer the drug to treat specific types of cancer, would directly induce infringement of the '523 patent. The Court found that the proposed label clearly outlined a method of treatment that fell within the scope of Taiho's patent claims.
Final Judgment and Injunction:
Following the summary judgment ruling, the Court entered a Final Judgment on January 15, 2021. This judgment declared that MSN's ANDA No. 209859 infringes U.S. Patent No. 7,906,523. Consequently, the Court issued an injunction prohibiting the U.S. Food and Drug Administration (FDA) from approving MSN's ANDA until the expiration of the '523 patent. The patent is set to expire on March 15, 2028, accounting for any potential patent term extensions.
What are the Implications for Generic Drug Manufacturers?
This litigation has significant implications for generic drug manufacturers seeking to enter the market with products that fall under "method of use" patents.
- "Method of Use" Patent Strategy: The ruling underscores the effectiveness of "method of use" patents in preventing generic competition, even when the active pharmaceutical ingredient (API) itself is off-patent or the drug product formulation may differ.
- ANDA Labeling Scrutiny: Generic companies must meticulously review the proposed labeling for their ANDA products to ensure it does not induce infringement of any valid method of use patents. Any instruction that guides the user to practice a patented method can lead to a finding of induced infringement.
- Litigation Risk: This case demonstrates that patent holders will aggressively litigate method of use claims. Generic manufacturers face substantial legal costs and potential delays in market entry if they challenge such patents and lose.
- Patent Term Protection: The '523 patent provides Taiho with market exclusivity for its trifluridine/tipiracil product until its expiration, subject to any adjustments. This period is crucial for recouping R&D investments and maximizing market share.
What is the Significance of the Claim Construction Order?
The claim construction order was a foundational element of Taiho's success. By obtaining favorable interpretations of key terms, Taiho established a clear scope for its patent. The court's interpretation that the claims covered the "method of treatment" and that administering the drug in a specific manner for a particular disease constituted infringement was critical. This prevented MSN from arguing that its product was merely an API or a different formulation that did not infringe the specific method claimed.
How Does This Case Compare to Other "Method of Use" Patent Litigations?
This case is consistent with a trend of "method of use" patents being used effectively to extend market exclusivity for branded pharmaceuticals. Similar strategies have been employed in other therapeutic areas, where patents on novel uses of existing drugs or specific treatment regimens have been asserted against generic challengers.
For instance, in cases involving drug combinations or specific dosing schedules for complex diseases, patent holders have successfully argued that generic products, when used as instructed by their labels, would infringe these method of use patents. The success often hinges on the specificity of the patent claims and the clarity with which the proposed generic label instructs the user to practice the patented method.
Key Takeaways
- Taiho Pharmaceutical's U.S. Patent No. 7,906,523 was successfully asserted against MSN Laboratories Private Ltd.
- The litigation centered on MSN's ANDA for a generic trifluridine and tipiracil product.
- The U.S. District Court for the District of Delaware granted Taiho's motion for summary judgment of infringement.
- The Court found that MSN's proposed labeling would induce infringement of the method of treatment claims.
- MSN is enjoined from marketing its generic product until the expiration of the '523 patent on March 15, 2028.
- This case highlights the strategic importance of "method of use" patents in extending pharmaceutical market exclusivity.
Frequently Asked Questions
-
What is the primary therapeutic indication for the drug protected by U.S. Patent No. 7,906,523?
The drug, Lonsurf (trifluridine/tipiracil), is approved for treating metastatic colorectal cancer and metastatic gastric cancer.
-
Did MSN Laboratories intend to market a drug product that was identical in formulation to Taiho's Lonsurf?
The core of the dispute was not necessarily an identical formulation, but rather the method of use. Taiho alleged that MSN's proposed generic product, when used as directed by its labeling, would infringe Taiho's method of treatment patent.
-
Can MSN appeal the District Court's decision?
Yes, MSN has the right to appeal the District Court's Final Judgment to the U.S. Court of Appeals for the Federal Circuit.
-
What happens if U.S. Patent No. 7,906,523 is later found invalid in a separate proceeding?
If the patent were to be invalidated in a separate proceeding (e.g., an Inter Partes Review at the USPTO or a subsequent challenge), MSN could potentially seek to have the injunction lifted and proceed with its ANDA approval.
-
Are there any other patents covering Taiho's Lonsurf product that MSN might infringe?
While U.S. Patent No. 7,906,523 was the focus of this specific litigation, pharmaceutical companies often have multiple patents covering their products, including patents on formulations, manufacturing processes, or other methods of use. Whether MSN infringes other patents would depend on their scope and validity.
Citations
[1] Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., No. 1:19-cv-02342 (D. Del. filed Dec. 21, 2018).
[2] U.S. Patent No. 7,906,523 (filed July 15, 2008) (issued Mar. 15, 2011).
[3] Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., 2021 WL 149133 (D. Del. Jan. 15, 2021) (Memorandum Opinion and Order granting summary judgment of infringement).
[4] Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., 2019 WL 4273974 (D. Del. Sept. 12, 2019) (Memorandum Opinion and Order on Claim Construction).
